SP
GILD icon

Saranac Partners’s Gilead Sciences GILD Stock Holding History

Saranac Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$246K Buy
+3,164
New +$443K 0.11% 83
2025
Q4 		– Sell
-1,060
Closed -$118K – 103
2025
Q3 		$118K Buy
+1,060
New +$120K 0.02% 237

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Saranac Partners's GILD Position: Q1 2026 in Review

Saranac Partners opened a new position in Gilead Sciences (GILD) in Q1 2026: 3,164 shares worth $246K. The stake represents 0.11% of the portfolio and ranks #83 among its holdings. This is a return to the name: Saranac Partners previously reported a position in GILD as recently as Q3 2025.

Saranac Partners first reported a position in GILD in Q3 2025 and has held it in 2 quarters since. 2,316 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Saranac Partners held 3,164 shares of Gilead Sciences worth $246K as of Q1 2026.
  • Gilead Sciences was a new Saranac Partners position in Q1 2026.
  • Gilead Sciences made up 0.11% of Saranac Partners's portfolio in Q1 2026, its #83 holding.
  • Saranac Partners first reported a position in Gilead Sciences in Q3 2025 and has held it in 2 quarters since.
  • 2,316 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Saranac Partners's 13F filing for Q1 2026, filed 15 May 2026.